AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02114892
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcined magnesia capsules, 500 mg, three times per day before meals with a total dose per day of 1500 mg
Trial: NCT02769091
Drug: TEV-45478
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg (2x40mg) tablets once daily for up to 24 weeks
Trial: NCT02769091
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01047683
Drug: AMR101 (ethyl icosapentate) - 4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks (Weeks 1-12)
Trial: NCT01047683
Drug: AMR101 (ethyl icosapentate) - 2 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMR101 (ethyl icosapentate) 2 capsules/day with placebo 2 capsules/day for 12 weeks (Weeks 1-12)
Trial: NCT01047683
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 4 capsules/day for 12 weeks (Weeks 1-12)
Trial: NCT03885921
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT03904680
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 2.5 mg tablet
Trial: NCT03989830
Drug: second-line chemotherapy
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: choose appropriate regimen according to efficacy and adverse effects of first-line chemotherapy. q3W regimen, 6 cycles.
Trial: NCT04870359
Drug: Prednisolone and/or AZA/MMF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone and/or AZA/MMF
Trial: NCT00839631
Drug: EC D-3263 HCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC D-3263 HCl, capsules, 50 mg. Oral administration. Dose escalation cohorts (cycle one: single dose on Day 1, daily doses on day 8-28; subsequent cycles: 1 week drug holiday followed by 3 weeks of daily dosing). Expansion Cohort: daily dosing for 28 days followed by a single 7 day drug holiday (Cycle 1), continuing thereafter with daily dosing.
Trial: NCT00190775
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered QD, orally for 24 weeks. At the end of 24 weeks, the placebo arm is titrated to atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 40-100 mg QD, orally.
Trial: NCT03547141
Drug: MBA-P01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection of MBA-P01 into the muscle of each contralateral foot in equal doses
Trial: NCT01668277
Drug: 7.2% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01668277
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02248922
Drug: TIS or TIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg nebulized Tobramycin (Tobramycin inhalation solution(TIS)) or TOBI Podhaler (Tobramycin inhalation powder(TIP), equivalent dry powder)
Trial: NCT02379858
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sugar pill-will be the same size and color as the Alvimopan capsule), 12mg capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
Trial: NCT04536194
Drug: norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: to treat hypotension under general anesthesia with norepinephrine
Trial: NCT04536194
Drug: dopamine
RxNorm normalized name: Dopamine
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: to treat hypotension under general anesthesia with dopamine
Trial: NCT02956811
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT03117335
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug 1:~Placebo(Sodium Chloride Injection),7.5mg/m2 on d1-d14 in each 21-day cycle（stop interventing until the disease progress）~Drug 2:~Vinorelbine-Cisplatin:~Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)
Trial: NCT03117335
Drug: Sulijia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug 1:~Sulijia(Recombinant Endostatin Injection) Sulijia, 7.5mg/m2 on d1-d14 in each 21-day cycle（stop interventing until the disease progress）~Drug 2:~Vinorelbine-Cisplatin:~Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)
Trial: NCT03338387
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Other Names: Placebo (for Olbetam)
Trial: NCT03097380
Drug: AZD2115
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD2115
Trial: NCT01339442
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02048904
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 pill/day for 3 months
Trial: NCT00441688
Drug: GI265235
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03369795
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 10mg once a week will be given for the first two weeks of the trial, followed by an increase in dose to 15mg or equivalent placebo once a week until week 16.
Trial: NCT04132050
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT03394950
Drug: rtPA
RxNorm normalized name: Sportpac Coldpac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysi with 0.9mg/kg rtPA, followed by other treatments according to guidelines
Trial: NCT01446211
Drug: cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Severe subgroup: will receive intravenous cyclophosphamide pulses for at least 13 weeks and 22 weeks at maximum, followed by methotrexate + glucocorticoids after achieving a response with BVAS ≤ 2. Patients intolerant to methotrexate and patients with impaired renal function will receive azathioprine + glucocorticoids .~Non-severe subgroup: will receive methotrexate + glucocorticoids (or azathioprine + glucocorticoids for those previously intolerant to methotrexate or with impaired renal function).
Trial: NCT00279747
Drug: meloxicam 0.25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00279747
Drug: naproxen 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01929070
Drug: HCP1007
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01929070
Drug: Omarco and Crestor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04769557
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00794586
Drug: FTI, AZLI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluation of 2 dosage combinations of fosfomycin and tobramycin inhaled twice daily for 28 days following 28 days of inhaled AZLI (Aztreonam Lysine for Inhalation)
Trial: NCT00794586
Drug: Placebo, AZLI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume-matched placebo inhaled twice daily for 28 days following 28 days of AZLI (Aztreonam Lysine for Inhalation).
Trial: NCT00083538
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02876978
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m\^2/day x 2 days
Trial: NCT01587989
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 15-25 mg orally weekly, Weeks 1-12
Trial: NCT01587989
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 15-25 mg orally weekly, Weeks 13-24
Trial: NCT01587989
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methotrexate placebo orally weekly, Weeks 13-24
Trial: NCT00642330
Drug: oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one (10 mg / kg), two (10 mg / kg followed 24 hours after by 5 mg /kg) or three (10 mg / kg followed at 24-hour intervals by two doses of 5 mg /kg each) doses of oral ibuprofen starting on the third day of life.the number of doses is depending on echocardiographic findings concerning ductal closure.
Trial: NCT00642330
Drug: intravenous ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: one (10 mg / kg), two (10 mg / kg followed 24 hours after by 5 mg /kg) or three (10 mg / kg followed at 24-hour intervals by two doses of 5 mg /kg each) doses of oral ibuprofen starting on the third day of life.the number of doses is depending on echocardiographic findings concerning ductal closure.
Trial: NCT02205450
Drug: Recombinant Somatropin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02385461
Drug: Low Molecular Weight Heparins (LMWHs)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03684655
Drug: [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]F-AraG is a radiolabeled high affinity substrate for deoxyguanosine kinase (dGK) and a low affinity substrate for deoxycytidine kinase (dCK), which are over-expressed in activated T cells.
Trial: NCT01116050
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 tablets in opque introducer
Trial: NCT02842931
Drug: R-DA-EPOCH-21
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-DA-EPOCH-21 treatment without auto-SCT for DLBCL patients younger than 60 years with intermediate and high risk for IPI
Trial: NCT02842931
Drug: R-DA-EPOCH-21 + auto-SCT
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-DA-EPOCH-21 treatment with auto-SCT for DLBCL patients younger than 60 years with intermediate and high risk for IPI
Trial: NCT02842931
Drug: R-mNHL-BFM-90
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-mNHL-BFM-90 without auto-SCT in patients with DLBCL under the age of 60 years with intermediate and high risk for IPI
Trial: NCT02842931
Drug: R-mNHL-BFM-90 + auto-SCT
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-mNHL-BFM-90 with auto-SCT in patients with DLBCL under the age of 60 years with intermediate and high risk for IPI
Trial: NCT02265913
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04331080
Drug: Granexin® gel 100 μM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
Trial: NCT04331080
Drug: Granexin® gel 200 μM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
Trial: NCT04331080
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
Trial: NCT00862251
Drug: ezetimibe (+) simvastatin
RxNorm normalized name: ezetimibe / simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks.
Trial: NCT00862251
Drug: simvastatin 40 mg or atorvastatin 20 mg
RxNorm normalized name: simvastatin 40 MG
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.
Trial: NCT00862251
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: rosuvastatin 10 mg tablets, taken once daily for six weeks.
Trial: NCT00862251
Drug: atorvastatin 10 mg or simvastatin 20 mg
RxNorm normalized name: simvastatin 10 MG
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will take atorvastatin 10 mg tablets OR simvastatin 20 mg tablets, taken once daily in a 6-week screening/stabilization period prior to randomization.
Trial: NCT01262898
Drug: GSK962040 (5 mg tablet)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tablet
Trial: NCT01262898
Drug: GSK962040 (25 mg tablet)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg tablet
Trial: NCT01262898
Drug: GSK962040 (125 mg tablet)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg tablet
Trial: NCT01262898
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablet
Trial: NCT00046722
Drug: Smoked Marijuana
RxNorm normalized name: Picea mariana resin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03304522
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received placebo matched to VX-150 for 6 weeks.
Trial: NCT02351115
Drug: A=Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02351115
Drug: E=Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01818544
Drug: BAY85-8501
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY85-8501 (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning
Trial: NCT01818544
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning
Trial: NCT02717091
Drug: FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01645709
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03532789
Drug: placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One patch without medicine should be applied to the skin every other day within two weeks
Trial: NCT04249882
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched to active medication
Trial: NCT02176486
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib placebo-matching capsules.
Trial: NCT01872013
Drug: ASP7991
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01872013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03233035
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL of normal saline solution as a placebo in one pulverisation per nostril
Trial: NCT01392833
Drug: azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azathioprine 1.5 mg/kg/day for six months followed by azathioprine 50 mg/day for a further six months.
Trial: NCT01814657
Drug: Sterile Normal Saline%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile normal saline used as placebo for lidocaine hydrochloride (HCl)1% solution
Trial: NCT01884298
Drug: remifentanil(Ultiva)
RxNorm normalized name: remifentanil Injection [Ultiva]
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: remifentanil (TCI, Ce 3 ng /ml)for intra-operative analgesia
Trial: NCT01470027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: effervescent tablets
Trial: NCT04558697
Drug: Hyperici extractum oleosum vagitories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperici extractum oleosum vagitories will be administered once daily for 5 days
Trial: NCT04558697
Drug: Vagitories - Probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vagitories - Probiotic will be administered once daily for 5 days
Trial: NCT01755169
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00098787
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00098787
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00864734
Drug: CLUCOVANCE® 5 mg/500 mg Tablets, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
Trial: NCT00643149
Drug: azithromycin SR
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg dose of azithromycin SR was as safe and effective as a 10-day regimen of amoxicillin when used to treat children with strep throat
Trial: NCT00201539
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: purchased from the manufacturer of morphine tablets (Nycomed Pharma, Oslo, Norway)
Trial: NCT02243787
Drug: COVA322
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02388321
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.
Trial: NCT00764725
Drug: conventional DMARD combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX+SSZ+Plaquenil; can be changed to MTX+cyclosporin within protocol
Trial: NCT01636557
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Type=exact number, unit=mg, number=100, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
Trial: NCT01311778
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All subjects will receive 0.5 mcg/kg and 1mcg/kg of Fentanyl (test session 1 and test session 2)
Trial: NCT03830671
Drug: 18-month regimen containing 6 anti-TB drugs
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational regimen:3Am-Mfx-PZA-X-Y-Z/3Am3-Mfx-PZA-X-Y-Z/12 Mfx-PZA-X-Y-Z.X、Y、Z are the drugs susceptible or possibly susceptible to mycobacterial bacilli(The candidated drugs to be selected are:Cs-Cycloserine,Pto-Protionamide,Clr-Clarithromycin,PAS-sodium para-aminosalicylate,E-ethambutol,Bdq-Bedaquiline,Cfz-Clofazimine,Lzd-linezolid).The abbreviation of the name of each drug in the regimen is explained as follows: PZA-pyrazinamide，Am-Amikacin，Mfx-moxifloxacin）and the total duration of the regimen is 18 months
Trial: NCT00508729
Drug: Qingyi granules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01244737
Drug: [18F] FLT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\] FLT, intravenous, at a dose of 0.15 mCi/kg once before a PET scan
Trial: NCT01274221
Drug: SPD489
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule per day throughout the open-label treatment phase and for one week of the double-blind crossover phase
Trial: NCT01225354
Drug: Calcium hydroxylapatite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be treated to full correction at visit 1 and, if needed, a touch-up injection at 2 weeks.
Trial: NCT03860506
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01901887
Drug: Study Juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention will be 3 boxes/day for 6 months of SMARTFISH® Nutrifriend 1100, a commercially available smoothie juice box containing 1,100 mg of omega-3 HUFAs/200 ml box (approximately 550 mg EPA and 550 mg DHA/box) for a total of 3,300 mg of omega-3 HUFAs/day (approximately 1,650 mg EPA and 1,650 mg DHA/day).
Trial: NCT01901887
Drug: Placebo Juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be 3 boxes/day for 6 months of a placebo juice which will be identical to the study juice except that it will substitute 1,100 mg of macadamia nut oil/200 ml juice box in place of the omega-3 HUFAs for a total of 3,300 mg of macadamia nut oil/day.
Trial: NCT00743795
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral BID
Trial: NCT01995890
Drug: nepafenac
RxNorm normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00384579
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00049348
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01339650
Drug: ABT-767
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-767 once or twice daily for a 28 day cycle
Trial: NCT02565641
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be administered orally at 830 mg/m\^2 BID (equivalent to a total daily dose of 1660 mg/m\^2) as intermittent treatment (given days 1 to 21 q4w).
Trial: NCT01494285
Drug: ARK-E021 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topically applied once daily at bedtime
Trial: NCT01494285
Drug: ARK-E021 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topically applied once daily at bedtime
Trial: NCT01494285
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topically applied once daily at bedtime
Trial: NCT01117376
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin 250 mg intravenous Q6h for 4 doses